5. Conclusion
Despite the higher levels of chemotherapy tolerance and the same
survival rate in NAC, AC has a favorable cost-effectiveness profile in
the NSCLC initial treatment phase. The cost-effectiveness analysis is
sensitive to survival at classic WTP thresholds. Based on the current
evidence, the NAC as a general ffirst choice treatment in cT2-4N0-1
NSCLC patients is not supported. To better assess the relative merits of
these therapeutic regimens, attention should not only be given to OS and
DFS, but also to the QOL and cost-effectiveness, especially when the
number of lung cancer patients and treatment burden increase greatly. In
view of the insufficiency in head to head trials and clinically enriched
dataset, the cost-effectiveness analysis of NAC and AC can benefit from
more cohort studies.